Overview

Description

  • NatureSynthetic

Associated products

Specifications

Our Abpromise guarantee covers the use of ab5853 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking

  • Purity> 95 % SDS-PAGE.

  • FormLiquid
  • Additional notes


    This peptide conjugate may be used for neutralization and control experiments with the monoclonal antibody that reacts with this product and human PAR4 , catalog ab5787. Using a solution of peptide of equal volume and concentration to the corresponding antibody will yield a large molar excess of peptide (70-fold) for competitive inhibition of antibody-protein binding reactions.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

General Info

  • Alternative names
    • 2310001G03Rik
    • PAR 4
    • PAR-4
    • Pawr
    • PAWR_HUMAN
    • PRKC Apoptosis WT1 Regulator
    • PRKC apoptosis WT1 regulator protein
    • Prostate apoptosis response 4 protein
    • Prostate apoptosis response protein 4
    • prostate apoptosis response protein PAR-4
    • Transcriptional repressor Par-4-like protein PAWR
    • Transcriptional repressor PAR4
    • WT1 Interacting Protein
    see all
  • FunctionPro-apoptopic protein capable of selectively inducing apoptosis in cancer cells, sensitizing the cells to diverse apoptotic stimuli and causing regression of tumors in animal models. Induces apoptosis in certain cancer cells by activation of the Fas prodeath pathway and coparallel inhibition of NF-kappa-B transcriptional activity. Inhibits the transcriptional activation and augments the transcriptional repression mediated by WT1. Down-regulates the anti-apoptotic protein BCL2 via its interaction with WT1. Seems also to be a transcriptional repressor by itself. May be directly involved in regulating the amyloid precursor protein (APP) cleavage activity of BACE1.
  • Tissue specificityWidely expressed. Expression is elevated in various neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer, Parkinson and Huntington diseases and stroke. Down-regulated in several cancers.
  • DomainThe leucine-zipper domain is not essential for apoptosis, but is required for sensitization of cells to exogenous apoptotic insults and for interaction with its partners.
    The SAC domain is a death-inducing domain selective for apoptosis induction in cancer cells. This domain is essential for nuclear entry, Fas activation, inhibition of NF-kappa-B activity and induction of apoptosis in cancer cells.
  • Post-translational
    modifications
    Preferentially phosphorylated at the Thr-163 by PKC in cancer cells.
  • Cellular localizationCytoplasm. Nucleus. Mainly cytoplasmic in absence of apoptosis signal and in normal cells. Nuclear in most cancer cell lines. Nuclear entry seems to be essential but not sufficient for apoptosis (By similarity). Nuclear localization includes nucleoplasm and PML nuclear bodies.
  • Information by UniProt

References for PAR4 peptide (ab5853)

ab5853 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab5853.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"